“…35, 36 In a preliminary study of 321 patients, Rex et al 34 found that administration of 45 mL plus 30 mL of NaP solution (75 mL regimen containing 49.5 g of NaP) resulted in significantly less pronounced mean shifts from baseline in several laboratory parameters, including serum sodium and phosphate levels, compared with administration of the standard 45 mL plus 45 mL regimen of NaP solution (90 mL regimen containing 59.4 g of NaP) (p ≤ 0.01).…”
Section: Serum Electrolyte Shifts and Safety Concernsmentioning
confidence: 98%
“…27 In addition, NaP solution is available in a lower-dose regimen of 75 mL versus 90 mL. 34 A limited number of studies, discussed below, suggest that administration of lower doses of NaP may translate into an improved safety profile with comparable or better efficacy. 34-36…”
Section: Composition Of Formulationsmentioning
confidence: 99%
“…5 In a study comparing 45 mL plus 30 mL of NaP solution versus the standard 45 mL plus 45 mL regimen, the lower dose regimen significantly reduced the incidence of vomiting (3% vs 8%; p = 0.04), abdominal cramps (36% vs 48%; p = 0.02), and overall discomfort (58% vs 69%; p = 0.03). 34 However, another study comparing these NaP liquid regimens failed to observe a difference in the frequency of reported AEs. 37 In a study comparing different NaP tablet formulations, Rex et al 35 reported significant reductions in the incidence of AEs (58% vs 68%; p = 0.03) and GI AEs (56% vs 66%; p < 0.05) in patients who received 32 MCC-free tablets (n = 239) compared with those who received 40 MCC-containing tablets (n = 238), respectively.…”
Section: Serum Electrolyte Shifts and Safety Concernsmentioning
confidence: 99%
“…A larger study of 321 subjects reported comparable cleansing with 90 mL and 75 mL regimens; good or excellent cleansing was reported in 90% of patients who took the 90 mL regimen and in 87% of patients who took the 75 mL regimen. 34 While these preliminary trials were not powered to establish equivalence between the study arms, they suggest very similar efficacy for the 90 mL and 75 mL preparations.…”
Section: Efficacy and Tolerabilitymentioning
confidence: 99%
“…The recommended dosing schedules for NaP preparations (Table 1) are supportedby severalclinicalstudies. [34][35][36][37][38][39][40][41][42][43][44][45][46] An importantcomponentof these schedules is split dosing, in which a portion of the dose is administered on the day before colonoscopy and the remaining dose is administeredon the day of the procedure.…”
Section: Split-dosing Schedules Aremosteffective and Potentially Safermentioning
Safe administration of NaP products requires rigorous attention to dosing considerations and other treatment recommendations, including administration of minimally effective doses of NaP, split-dosing schedules, and aggressive hydration.
“…35, 36 In a preliminary study of 321 patients, Rex et al 34 found that administration of 45 mL plus 30 mL of NaP solution (75 mL regimen containing 49.5 g of NaP) resulted in significantly less pronounced mean shifts from baseline in several laboratory parameters, including serum sodium and phosphate levels, compared with administration of the standard 45 mL plus 45 mL regimen of NaP solution (90 mL regimen containing 59.4 g of NaP) (p ≤ 0.01).…”
Section: Serum Electrolyte Shifts and Safety Concernsmentioning
confidence: 98%
“…27 In addition, NaP solution is available in a lower-dose regimen of 75 mL versus 90 mL. 34 A limited number of studies, discussed below, suggest that administration of lower doses of NaP may translate into an improved safety profile with comparable or better efficacy. 34-36…”
Section: Composition Of Formulationsmentioning
confidence: 99%
“…5 In a study comparing 45 mL plus 30 mL of NaP solution versus the standard 45 mL plus 45 mL regimen, the lower dose regimen significantly reduced the incidence of vomiting (3% vs 8%; p = 0.04), abdominal cramps (36% vs 48%; p = 0.02), and overall discomfort (58% vs 69%; p = 0.03). 34 However, another study comparing these NaP liquid regimens failed to observe a difference in the frequency of reported AEs. 37 In a study comparing different NaP tablet formulations, Rex et al 35 reported significant reductions in the incidence of AEs (58% vs 68%; p = 0.03) and GI AEs (56% vs 66%; p < 0.05) in patients who received 32 MCC-free tablets (n = 239) compared with those who received 40 MCC-containing tablets (n = 238), respectively.…”
Section: Serum Electrolyte Shifts and Safety Concernsmentioning
confidence: 99%
“…A larger study of 321 subjects reported comparable cleansing with 90 mL and 75 mL regimens; good or excellent cleansing was reported in 90% of patients who took the 90 mL regimen and in 87% of patients who took the 75 mL regimen. 34 While these preliminary trials were not powered to establish equivalence between the study arms, they suggest very similar efficacy for the 90 mL and 75 mL preparations.…”
Section: Efficacy and Tolerabilitymentioning
confidence: 99%
“…The recommended dosing schedules for NaP preparations (Table 1) are supportedby severalclinicalstudies. [34][35][36][37][38][39][40][41][42][43][44][45][46] An importantcomponentof these schedules is split dosing, in which a portion of the dose is administered on the day before colonoscopy and the remaining dose is administeredon the day of the procedure.…”
Section: Split-dosing Schedules Aremosteffective and Potentially Safermentioning
Safe administration of NaP products requires rigorous attention to dosing considerations and other treatment recommendations, including administration of minimally effective doses of NaP, split-dosing schedules, and aggressive hydration.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.